{"title": "Hexyon - European Medicines Agency", "author": "EMA; COMM; DG; UNIT", "url": "https://www.ema.europa.eu/en/medicines/human/EPAR/hexyon", "hostname": "europa.eu", "description": "Hexyon", "sitename": "European Medicines Agency", "date": "2018-09-17", "cleaned_text": "and Haemophilus influenzae type b conjugate vaccine (adsorbed) Table of contents Overview This is a summary of the [European public assessment report](/en/glossary/european-public-assessment-report) (EPAR) for Hexyon. It explains how the Agency assessed the medicine to recommend its authorisation in the European Union (EU) and its conditions of use. It is not intended to provide practical advice on how to use Hexyon. For practical information about using Hexyon, patients should read the [package leaflet](/en/glossary/package-leaflet) or contact their doctor or pharmacist. - List item Hexyon : EPAR - Summary for the public (PDF/85.69 (INN) or common name|| | diphtheria, tetanus, pertussis (acellular, component), hepatitis B (rDNA), |Date of issue of marketing authorisation valid throughout the European Union|| | This medicine's [product information](/en/glossary/product-information) available in all official EU languages. Select 'available languages' to access the language you need. [Product information](/en/glossary/product-information) contain: [summary of product characteristics](/en/glossary/summary-product-characteristics)(annex I); - manufacturing authorisation holder responsible for batch release (annex IIA); - documents for centrally authorised human medicines on this website. For centrally authorised veterinary medicines authorised or updated from February 2022, see the [Veterinary Medicines Information website](https://www.medicinesinfo.eu/). Pharmacotherapeutic group Vaccines Therapeutic indication Hexyon (DTaP-IPV-HB-Hib) is indicated for primary and booster vaccination of infants and toddlers from six weeks of age against diphtheria, tetanus, pertussis, hepatitis B, poliomyelitis and invasive diseases caused by Haemophilus influenzae type b (Hib). The use of this vaccine should be in accordance with official recommendations. "}